» Articles » PMID: 33808051

Cytokine-Induced Memory-Like NK Cells with High Reactivity Against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches

Abstract

The limited efficacy of Natural Killer (NK) cell-based immunotherapy results in part from the suboptimal expansion and persistence of the infused cells. Recent reports suggest that the generation of NK cells with memory-like properties upon in vitro activation with defined cytokines might be an effective way of ensuring long-lasting NK cell function in vivo. Here, we demonstrate that activation with IL-12, IL-15 and IL-18 followed by a one-week culture with optimal doses of Interleukin (IL-2) and IL-15 generates substantial numbers of memory-like NK cells able to persist for at least three weeks when injected into NOD scid gamma (NSG) mice. This approach induces haploidentical donor-derived memory-like NK cells that are highly lytic against patients' myeloid or lymphoid leukemia blasts, independent of the presence of alloreactive cell populations in the donor and with negligible reactivity against patients' non-malignant cells. Memory-like NK cells able to lyse autologous tumor cells can also be generated from patients with solid malignancies. The anti-tumor activity of allogenic and autologous memory-like NK cells is significantly greater than that displayed by NK cells stimulated overnight with IL-2, supporting their potential therapeutic value both in patients affected by high-risk acute leukemia after haploidentical hematopoietic stem cell transplantation and in patients with advanced solid malignancies.

Citing Articles

The innate defenders: a review of natural killer cell immunotherapies in cancer.

Alvarez-Carrasco P, Maldonado-Bernal C Front Immunol. 2025; 15:1482807.

PMID: 39763648 PMC: 11700995. DOI: 10.3389/fimmu.2024.1482807.


Natural killer cells and engagers: Powerful weapons against cancer.

Bottino C, Picant V, Vivier E, Castriconi R Immunol Rev. 2024; 328(1):412-421.

PMID: 39180430 PMC: 11659922. DOI: 10.1111/imr.13384.


Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells.

Lakshmi Thangaraj J, Coffey M, Lopez E, Kaufman D Cell Stem Cell. 2024; 31(9):1327-1343.e5.

PMID: 38986609 PMC: 11380586. DOI: 10.1016/j.stem.2024.06.009.


The application of autologous cancer immunotherapies in the age of memory-NK cells.

Lizana-Vasquez G, Torres-Lugo M, Dixon R, Powderly 2nd J, Warin R Front Immunol. 2023; 14:1167666.

PMID: 37205105 PMC: 10185894. DOI: 10.3389/fimmu.2023.1167666.


iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.

Dong Y, Huang Y, Zhang Z, Chen A, Li L, Tian M J Transl Med. 2023; 21(1):205.

PMID: 36932395 PMC: 10022190. DOI: 10.1186/s12967-023-04024-7.


References
1.
Locatelli F, Pende D, Falco M, Della Chiesa M, Moretta A, Moretta L . NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. Trends Immunol. 2018; 39(7):577-590. DOI: 10.1016/j.it.2018.04.009. View

2.
Bono M, Pende D, Bertaina A, Moretta A, Della Chiesa M, Sivori S . Analysis of Polymorphism Provides Relevant Information on Centromeric Gene Content. J Immunol. 2018; 201(5):1460-1467. DOI: 10.4049/jimmunol.1800564. View

3.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W, Tosti A . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562):2097-100. DOI: 10.1126/science.1068440. View

4.
Bachanova V, Cooley S, DeFor T, Verneris M, Zhang B, McKenna D . Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014; 123(25):3855-63. PMC: 4064329. DOI: 10.1182/blood-2013-10-532531. View

5.
Yoon S, Lee Y, Yang S, Ahn K, Lee J, Lee J . Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2009; 45(6):1038-46. DOI: 10.1038/bmt.2009.304. View